CAR T cell therapy for B-cell lymphomas.

[1]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[2]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[3]  M. Kersten,et al.  Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017 .

[4]  Michael L. Wang,et al.  Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration , 2017 .

[5]  Michael L. Wang,et al.  High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort , 2017 .

[6]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[7]  S. Rosenberg,et al.  Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  V. Calvo,et al.  Prognostic value of event‐free survival at 12 and 24 months and long‐term mortality for non‐Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group , 2017, Cancer.

[9]  B. A. Aksoy,et al.  PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells , 2017, Front. Immunol..

[10]  G. Salles,et al.  Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis , 2017 .

[11]  Michael L. Wang,et al.  HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B‐NHL TREATED WITH THE CD19‐DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001) , 2017 .

[12]  Michael L. Wang,et al.  CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). , 2017 .

[13]  D. Miklos,et al.  Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). , 2017 .

[14]  J. Vose,et al.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Riddell,et al.  Fully human CD19-specific chimeric antigen receptors for T-cell therapy , 2017, Leukemia.

[17]  E. Kimby,et al.  Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Schmitz,et al.  Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study , 2017, Bone Marrow Transplantation.

[19]  Zheng Zhou,et al.  Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies , 2017, American journal of hematology.

[20]  Christopher A. Miller,et al.  Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. , 2017, Blood.

[21]  N. Bartlett,et al.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  D. Porter,et al.  Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy , 2016 .

[23]  M. Stetler-Stevenson,et al.  Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) , 2016 .

[24]  M. Crump.  Management of Relapsed Diffuse Large B-cell Lymphoma. , 2016, Hematology/oncology clinics of North America.

[25]  P. Porter,et al.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues , 2016, Clinical Cancer Research.

[26]  J. Cerhan,et al.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma , 2016, American journal of hematology.

[27]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[28]  Sonali M. Smith,et al.  Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 , 2016, British journal of haematology.

[29]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[30]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[31]  Hao Liu,et al.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. , 2016, The Journal of clinical investigation.

[32]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[33]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[34]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[35]  Y. Chen,et al.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells , 2016, Cancer Immunology Research.

[36]  J. Byrd,et al.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.

[37]  D. Maloney,et al.  Accepted Article Preview : Published ahead of advance online publication , 2016 .

[38]  B. Savoldo,et al.  Chimeric antigen receptor-redirected T cells return to the bench. , 2016, Seminars in immunology.

[39]  D. Porter,et al.  Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas , 2015 .

[40]  T. Fry,et al.  Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22 , 2015 .

[41]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[42]  Ken H. Young,et al.  Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.

[43]  L. Sehn,et al.  Outcome prediction by extranodal involvement, IPI, R‐IPI, and NCCN‐IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse‐large B‐cell lymphoma , 2015, American journal of hematology.

[44]  L. Staudt,et al.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens , 2015, Proceedings of the National Academy of Sciences.

[45]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[46]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[47]  J. Cerhan,et al.  Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 , 2015, American journal of hematology.

[48]  Michel Sadelain,et al.  CAR therapy: the CD19 paradigm. , 2015, The Journal of clinical investigation.

[49]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Staudt,et al.  Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Schuster,et al.  Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis , 2015, British journal of haematology.

[52]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Yang Liu,et al.  Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. , 2014, Clinical immunology.

[54]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[55]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[56]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[57]  Bingshu E. Chen,et al.  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[59]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[60]  J. Burke,et al.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.

[61]  J. Cerhan,et al.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[63]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[64]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[65]  Rita Coutinho,et al.  Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  R. Mick,et al.  Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era , 2013, American journal of hematology.

[67]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[68]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[69]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[70]  M. Kaminski,et al.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Cerhan,et al.  Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study , 2013, Cancer.

[72]  S. Barrans,et al.  Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B‐cell lymphoma and predict clinical outcome , 2012, British journal of haematology.

[73]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[75]  S. Steinberg,et al.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.

[76]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Rosenwald,et al.  MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .

[78]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[79]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[80]  A. Rosenwald,et al.  Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles , 2011, Haematologica.

[81]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[82]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[83]  E. Giné,et al.  Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.

[84]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[85]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[86]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[87]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[88]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[89]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[90]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[92]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[94]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[95]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[97]  W. Wilson,et al.  Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.

[98]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[99]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[100]  P. Greenberg,et al.  Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1 , 2008, The Journal of Immunology.

[101]  Yana Zhang,et al.  B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period , 2008, Leukemia & lymphoma.

[102]  R. Gascoyne,et al.  Clinical Trials and Observations , 2007 .

[103]  Philip M Kluin,et al.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[105]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[106]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[107]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[108]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[109]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[110]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[111]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[112]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[113]  J. Kochenderfer,et al.  Chimeric antigen receptor T-cell therapies for lymphoma , 2018, Nature Reviews Clinical Oncology.

[114]  W. Chan,et al.  Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  N. Schmitz,et al.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study , 2016, Bone Marrow Transplantation.

[116]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[117]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2014, Leukemia.

[118]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[119]  R. Scheuermann,et al.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. , 1995, Leukemia & lymphoma.